Rocket Pharmaceuticals Depreciation & Amortization Growth & History (RCKT)

Rocket Pharmaceuticals's depreciation and amortization was $8.9M for fiscal 2025.

View full Rocket Pharmaceuticals company overview

Rocket Pharmaceuticals annual depreciation and amortization history

Rocket Pharmaceuticals annual depreciation and amortization

Fiscal yearPeriod endedDepreciation and amortizationChangeGrowth
20252025-12-31$8.9M$1.7M+23.61%
20242024-12-31$7.2M$2.3M+46.94%
20232023-12-31$4.9M$1.0M+25.64%
20222022-12-31$3.9M$700,000+21.88%
20212021-12-31$3.2M$2.1M+179.48%
20202020-12-31$1.1M$719,000+168.78%
20192019-12-31$426,000$96,000+29.09%
20182018-12-31$330,000$126,000+61.76%
20172017-12-31$204,000$137,000+204.48%
20162016-12-31$67,000$22,000+48.89%
20152015-12-31$45,000$45,000
20142014-12-31$0

Rocket Pharmaceuticals depreciation and amortization trends

Over the last five fiscal years, Rocket Pharmaceuticals's depreciation and amortization increased from $1.1M to $8.9M, a change of $7.8M. The latest reported quarter, Q2 2026, shows $1.6M.

About the metric

What depreciation and amortization mean

Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.

Calculation and source

Reported depreciation and amortization

TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Rocket Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about RCKT yet. Start the conversation.

Write the first post